New H1/H3antagonists for treating allergic rhinitis: WO2010094643
Author:
- 23 February 2011
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 21 (3) , 425-429
Abstract
This application claims dual receptor specificity antihistamines, active as H(1) and H(3) antagonists, which additionally have a long duration of action that renders them suitable for once daily administration via inhalation for the treatment of allergic rhinitis. The compounds lack CNS penetration and have a high affinity for both histamine receptors.Keywords
This publication has 9 references indexed in Scilit:
- The expanding role of H1antihistamines: a patent survey of selective and dual activity compounds 2005 – 2010Expert Opinion on Therapeutic Patents, 2010
- Recent advances in histamine H3receptor antagonists/inverse agonistsExpert Opinion on Therapeutic Patents, 2010
- Recent disclosures of clinical candidatesDrugs of the Future, 2010
- Histamine H3and H4receptors as novel drug targetsExpert Opinion on Investigational Drugs, 2009
- Histamine H3 Receptor Antagonists Go to ClinicsBiological and Pharmaceutical Bulletin, 2008
- 4-Acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a Novel Class of Non-Brain-Penetrant Histamine H3 Receptor AntagonistsJournal of Medicinal Chemistry, 2007
- A H3antagonist for treating allergic rhinitis: a development candidate?Expert Opinion on Therapeutic Patents, 2007
- Histamine receptors that influence blockage of the normal human nasal airwayBritish Journal of Pharmacology, 2005
- Autoregulation of histamine release in brain by presynaptic H3-receptorsNeuroscience, 1985